| Nurix Therapeutics, Inc. (NRIX) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Q3-CY2026 | Q2-CY2026 | Q1-CY2026 | Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | |
| Balance Sheet Date | 2026-May-31 | 2026-Feb-28 | 2025-Nov-30 | 2025-Aug-31 | 2025-May-31 | 2025-Feb-28 | 2024-Nov-30 | 2024-Aug-31 | 2024-May-31 | 2024-Feb-29 | 2023-Nov-30 | 2023-Aug-31 | 2023-May-31 | 2023-Feb-28 | 2022-Nov-30 | 2022-Aug-31 | 2022-May-31 | 2022-Feb-28 | 2021-Nov-30 | 2021-Aug-31 | 2021-May-31 | 2021-Feb-28 | 2020-Nov-30 | 2020-Aug-31 | |||||||||||||||||||||||||
| Fiscal Period | Q2-FY2026 | Q1-FY2026 | Q4-FY2025 | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q1-FY2024 | Q4-FY2023 | Q3-FY2023 | Q2-FY2023 | Q1-FY2023 | Q4-FY2022 | Q3-FY2022 | Q2-FY2022 | Q1-FY2022 | Q4-FY2021 | Q3-FY2021 | Q2-FY2021 | Q1-FY2021 | Q4-FY2020 | Q3-FY2020 | |||||||||||||||||||||||||
| Operating Cash Flow | (96,573,000$) | (71,914,000$) | (67,832,000$) | (57,385,000$) | (63,161,000$) | (61,087,000$) | (48,751,000$) | (42,177,000$) | (39,705,000$) | (41,951,000$) | 26,689,000$ | (41,133,000$) | (18,469,000$) | (48,452,000$) | (37,955,000$) | (46,308,000$) | (32,914,000$) | (42,630,000$) | (30,911,000$) | (29,972,000$) | (31,535,000$) | 8,053,000$ | (20,482,000$) | (14,429,000$) | 40,972,000$ | (12,748,000$) | |||||||||||||||||||||||
| Investing Cash Flow | 92,997,000$ | (123,826,000$) | 346,000$ | 50,475,000$ | 71,499,000$ | 25,533,000$ | (140,817,000$) | (21,339,000$) | (131,070,000$) | 35,513,000$ | (14,373,000$) | 22,775,000$ | 43,831,000$ | 16,068,000$ | 55,008,000$ | (63,076,000$) | (4,765,000$) | 40,031,000$ | (36,523,000$) | (12,231,000$) | (57,110,000$) | (2,387,000$) | (124,563,000$) | (2,336,000$) | (19,424,000$) | (4,365,000$) | |||||||||||||||||||||||
| Purchases of Property and Equipment | 1,936,000$ | 1,045,000$ | 5,131,000$ | 2,711,000$ | 2,675,000$ | 3,485,000$ | 2,105,000$ | 2,347,000$ | 1,937,000$ | 2,884,000$ | 2,585,000$ | 2,459,000$ | 1,080,000$ | 2,277,000$ | 2,565,000$ | 3,418,000$ | 2,789,000$ | 3,472,000$ | 862,000$ | 1,865,000$ | 2,091,000$ | 843,000$ | 906,000$ | 1,613,000$ | 364,000$ | 953,000$ | |||||||||||||||||||||||
| Financing Cash Flow | 66,000$ | 19,975,000$ | 236,008,000$ | 1,155,000$ | 6,000$ | 1,473,000$ | 200,521,000$ | 45,770,000$ | 237,752,000$ | 1,624,000$ | 7,000$ | 1,704,000$ | 25,000$ | 1,481,000$ | (135,000$) | 115,407,000$ | 432,000$ | 1,488,000$ | 500,000$ | 1,552,000$ | 150,471,000$ | 1,359,000$ | (1,126,000$) | 119,684,000$ | 46,000$ | 80,000$ | |||||||||||||||||||||||
| End Cash Position | 67,685,000$ | 71,195,000$ | 246,960,000$ | 78,438,000$ | 84,260,000$ | 75,916,000$ | 109,997,000$ | 99,044,000$ | 116,790,000$ | 49,813,000$ | 54,627,000$ | 42,304,000$ | 58,958,000$ | 33,571,000$ | 64,474,000$ | 47,556,000$ | 41,533,000$ | 78,780,000$ | 80,506,000$ | 147,440,000$ | 188,207,000$ | 126,381,000$ | 119,356,000$ | 265,527,000$ | 159,329,000$ | 56,410,000$ | 34,816,000$ | 51,849,000$ | |||||||||||||||||||||
| Exchange Rate Effect | |||||||||||||||||||||||||||||||||||||||||||||||||
| Dividends Paid | |||||||||||||||||||||||||||||||||||||||||||||||||
| Unlevered Free Cash Flow | (98,509,000$) | (72,959,000$) | (72,963,000$) | (60,096,000$) | (65,836,000$) | (64,572,000$) | (50,856,000$) | (44,524,000$) | (41,642,000$) | (44,835,000$) | 24,104,000$ | (43,592,000$) | (19,549,000$) | (50,729,000$) | (40,520,000$) | (49,726,000$) | (35,703,000$) | (46,102,000$) | (31,773,000$) | (31,837,000$) | (33,626,000$) | 7,210,000$ | (21,388,000$) | (16,042,000$) | 40,608,000$ | (13,701,000$) | |||||||||||||||||||||||